Tiziana life sciences announces purchase of common shares by chief medical officer

New york, sept. 29, 2022 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that matthew davis, its chief medical officer, purchased 25,000 common shares at $0.75 per share, bringing his total holding to 200,000 common shares.
TLSA Ratings Summary
TLSA Quant Ranking